[1] HE B, LU C, ZHENG G, et al. Combination therapeutics in complex diseases[J].J Cell Mol Med, 2016, 20(12): 2231-2240. DOI: 10.1111/jcmm.12930.
[2] 吴天怡,龚妍春,李资玲,等.抗癌纳米药物共递送系统的应用研究[J].材料导报,2020, 34(S1):516-522.
[3] DANIEL T M, BATES J H, DOWNES K A. History of tuberculosis[J]. Tuberculosis, 1994: 13-24. DOI: 10.1128/9781555818357.ch2.
[4] WANG Y, ZHANG X, HAN Y, et al. Efficacy of combined medication of nifedipine and magnesium sulfate on gestational hypertension and the effect on PAPP-A, VEGF, NO, Hcy and vWF[J]. Saudi J Biol Sci, 2019, 26(8): 2043-2047. DOI: 10.1016/j.sjbs.2019.08.012.
[5] KAVITT R T, LIPOWSKA A M, ANYANE-YEBOA A, et al. Diagnosis and treatment of peptic ulcer disease[J]. Am J Med, 2019, 132(4): 447-456. DOI: 10.1016/j.amjmed.2018.12.009.
[6] 国家药品监督管理局药品审评中心.关于发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》的通告(2021年第46号)[EB/OL].https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7ab2f5.
[7] CHOU T C, TALALAY P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors[J]. Adv Enzyme Regul, 1984, 22: 27-55. DOI: 10.1016/0065-2571(84)90007-4.
[8] CHOU T C, MOTZER R J, TONG Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design[J]. J Nati Cancer Inst, 1994, 86(20): 1517-1524. DOI: 10.1093/jnci/86.20.1517.
[9] KAUFMANN S H, PEEREBOOM D, BUCKWALTER C A, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines[J]. J Nati Cancer Inst, 1996, 88(11): 734-741. DOI: 10.1093/jnci/88.11.734.
[10] GOPINATH H, KARTHIKEYAN K. Turmeric: A condiment, cosmetic and cure[J]. Indian J Dermatol Venereol Leprol, 2018, 84(1):16-21. DOI: 10.4103/ijdvl.IJDVL_1143_16.
[11] 任婧,张丹参,侯文书,等.姜黄素长循环脂质体的制备及表征[J].河北科技大学学报,2018, 39(6):532-539. DOI: 10.7535/hbkd.2018yx06008.
[12] ODOT J, ALBERT P, CARLIER A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells[J]. Int J Cancer, 2004, 111(3):381-387. DOI: 10.1002/ijc.20160.
[13] DU B Y, JIANG L P, XIA Q, et al. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29[J]. Chemotherapy, 2006, 52(1):23-28. DOI: 10.1159/000090238.
[14] 宋鹏锦,韩啸,孙彩凤,等.新型肝动脉栓塞微球制剂的制备[J].河北大学学报(自然科学版),2022, 42(2):150-157. DOI: 10.3969/j.issn.10001565.2022.02.007.
[15] GIORDANO A, TOMMONARO G. Curcumin and Cancer[J]. Nutrients, 2019, 11(10):2376. DOI: 10.3390/nu11102376.
[16] 李海鹰,邱明恒,陈健,等.L-精氨酸基姜黄素衍生物的合成及抑菌性评价[J].河北大学学报(自然科学版),2021, 41(2):155-160. DOI: 10.3969/j.issn.10001565.2021.02.007.
[17] BHATT L, SEBASTIAN B, JOSHI V. Mangiferin protects rat myocardial tissue against cyclophosphamide induced cardiotoxicity[J]. J Ayurveda Integr Med, 2017, 8(2): 62-67. DOI: 10.1016/j.jaim.2017.04.006.
[18] ROSENBERG B, VANCAMP L, KRIGAS T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode[J]. Nature, 1965, 205(4972):698-699. DOI: 10.1038/205698a0.
[19] LOH G W, TING L S, ENSOM M H. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy[J]. Clin Pharmacokinet, 2007, 46(6):471-494. DOI: 10.2165/00003088-200746060-00002.
[20] 王悦璇,刘秀均.顺铂的作用靶点及耐药机制的研究进展[J].中国医药生物技术, 2020, 15(3):316-319. DOI: 10.3969/j.issn.1673-713X.2020.03.016.
[21] 夏叶舟,谭小武,曾赛丽.姜黄素联合顺铂对肺癌 A549 细胞侵袭转移的影响及其可能机制[J].中国呼吸与危重监护杂志,2017, 16(6):581-585. DOI: 10.7507/1671-6205.201706015.
[22] CHENG Y, ZHAO P X, WU S P, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma[J]. Int J Pharm, 2018, 545(1-2): 261-273. DOI: 10.1016/j.ijpharm.2018.05.007.
[23] SANDHIUTAMI N M D, AROZAL W, LOUISA M, et al. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA[J]. Front Pharmacol, 2021, 11:603235. DOI: 10.3389/fphar.2020.603235.
[24] KUMAR P, BARUA C C, SULAKHIYA K, et al. Curcumin ameliorates cisplatin-induced nephrotoxicity and potentiates its anticancer activity in SD rats: potential role of curcumin in breast cancer chemotherapy[J]. Front Pharmacol, 2017, 8:132. DOI: 10.3389/fphar.2017.00132.
[25] ABDULLAH S, EL HADAD S, ALDAHLAWI A. The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells[J]. Int J Pharm, 2022, 613:121406. DOI: 10.1016/j.ijpharm.2021.121406.
[26] 孙维彤,陈倩倩,张娜,等.5-氟 尿 嘧 啶 前 体 药 物 研 究 进 展[J].生 命 的 化 学,2014, 34(02): 269-274. DOI: 10.13488/j.smhx.20140222.
[27] VALENCIA-LAZCANO AA, HASSAN D, POURMADADI M, et al. 5-Fluorouracil nano-delivery systems as a cutting-edge for cancer therapy[J]. Eur J Med Chem, 2023, 246: 114995. DOI: 10.1016/j.ejmech.2022.114995.
[28] 梁婧,皮超,冯婷,等.姜黄素/5-FU 对 肝 癌 细 胞 的 生 长 抑 制 作 用[J].时 珍 国 医 国 药,2018, 29(2):272-274. DOI:10.3969/j.issn.1008-0805.2018.02.006.
[29] 秦文兵,李瑞佳,张月丽.姜黄素对食管癌细胞中 5-FU 化疗敏感性的影响[J].中成药,2023, 45(3):960-964. DOI: 10.3969/j.issn.1001-1528.2023.03.047.
[30] PENDLETON E G, JAMASBI R J, GEUSZ M E. Tetrahydrocurcumin, curcumin, and 5-Fluorouracil effects on human esophageal carcinoma cells[J]. Anticancer Agents Med Chem, 2019, 19(8):1012-1020. DOI: 10.2174/1871520619666190116141448.
[31] BIDWELL G L 3rd, FOKT I, PRIEBE W, et al. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin[J]. Biochem Pharmacol, 2007, 73(5):620-631. DOI: 10.1016/j.bcp.2006.10.028.
[32] 杨学礼,张红蕾,杨瑜涛,等.HPLC 法测定 DNA 纳米运输系统载药阿霉素的含量[J].药物分析杂志,2019, 39(7):1239-1243. DOI: 10.16155/j.0254-1793.2019.07.10.
[33] JAWAD B, POUDEL L, PODGORNIK R, et al. Molecular mechanism and binding free energy of doxorubicin intercalation in DNA[J]. Phys Chem Chem Phys, 2019, 21(7):3877-3893. DOI: 10.1039/c8cp06776g.
[34] PETER S, ALVEN S, MASEKO R B, et al. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review[J]. Molecules, 2022, 27(14):4478. DOI: 10.3390/molecules27144478.
[35] 王磊,柯红,王一羽,等.联合应用阿霉素和姜黄素增强人白血病细胞株HL-60对阿霉素的敏感性[J].时珍国医国药,2009, 20(2): 418-420.
[36] 周思颖,张思杰,徐寒子,等.姜黄素脂质体通过调节 miRNA 的表达改变乳腺癌细胞对阿霉素的化疗敏感性[J].南京中医药大学学报, 2018, 34(3):312-317. DOI: 10.14148/j.issn.1672-0482.2018.0312.
[37] GUO W, SONG Y Y, SONG W T, et al. Co-delivery of doxorubicin and curcumin with polypeptide nanocarrier for synergistic lymphoma therapy[J]. Sci Rep, 2020, 10(1):7832. DOI: 10.1038/s41598-020-64828-1.
[38] ZHAO X J, CHEN Q, LIU W, et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer[J]. Int J Nanomedicine, 2015, 10:257-270. DOI: 10.2147/IJN.S73322.
[39] ZHU L Y, CHEN L Q. Progress in research on paclitaxel and tumor immunotherapy[J]. Cell Mol Biol Lett, 2019, 24: 40. DOI: 10.1186/s11658-019-0164-y.
[40] AHMED KHALIL A, RAUF A, ALHUMAYDHI F A, et al. Recent developments and anticancer therapeutics of paclitaxel: an update[J]. Curr Pharm Des, 2022, 28(41): 3363-3373. DOI: 10.2174/1381612829666221102155212.
[41] 王煦鑫,朱华结.手性化合物立体结构鉴定中的若干关键共性科学问题探讨[J].高等学校化学学报,2021, 42(6):1685-1693. DOI: 10.7503/cjcu20200726.
[42] YANG Y H, MAO J W, TAN X L. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel[J]. Chin J Nat Med, 2020, 18(12): 890-897. DOI: 10.1016/S1875-5364(20)60032-2.
[43] 刘冠媛,梁华茂,曾新红,等.紫杉醇和姜黄素联用对人卵巢癌细胞系 OC_3的抑制作用[J].山东大学学报(医学版), 2004, 42(3): 325-7+31.
[44] GANTA S, DEVALAPALLY H, AMIJI M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation[J]. J Pharm Sci, 2010, 99(11):4630-4641. DOI: 10.1002/jps.22157.
[45] 刘敏,张君,李俊福,等.姜黄素联合紫杉醇对人口腔鳞癌细胞的增殖抑制及凋亡诱导作用[J].上海口腔医学, 2016, 25(5):538-541.
[46] 齐瑞芳,石瑞丽,吕军,等.姜黄素联合紫杉醇在体内外可协同降低乳腺癌MDA-MB-231细胞迁移能力并降低MMP9表达[J].中药药理与临床, 2016, 32(01):83-85. DOI: 10.13412/j.cnki.zyyl.2016.01.023.
[47] CALAF G M, PONCE-CUSI R, CARRIÓN F. Curcumin and paclitaxel induce cell death in breast cancer cell lines[J]. Oncol Rep, 2018, 40(4):2381-2388. DOI: 10.3892/or.2018.6603.
[48] ZHONG L, LI Y S, XIONG L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives[J]. Signal Transduct Target Ther, 2021, 6(1):201. DOI: 10.1038/s41392-021-00572-w.
[49] 胡宏祥,王学清,张华,等.分子靶向抗肿瘤药物的作用机制及临床研究进展[J].药学学报, 2015, 50(10): 1232-1239.DOI:10.16438/j.0513-4870.2015.10.024.
[50] XIA S J, PAN Y, LIANG Y L, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma[J].EBioMedicine, 2020, 51:102610. DOI: 10.1016/j.ebiom.2019.102610.
[51] 吴紫阳,于之恒,王志妍,等.吉非替尼个体差异指标的临床研究现状[J].中国临床药理学杂志,2020, 36(4):458-461. DOI: 10.13699/j.cnki.1001-6821.2020.04.021.
[52] 胡博,孙超,孙鼎,等.姜黄素纳米粒(NanoCurc~(TM))联合索拉非尼对肝细胞癌(HCC)的协同抑制作用[J].复旦学报(医学版), 2014, 41(2):143-148. DOI: 10.3969/j.issn.1672-8467.2014.02.001.
[53] 朱怡卿,王芳.脂质体姜黄素联合索拉非尼对人肝癌 Huh7细胞的抑制作用[J].中国医学物理学杂志, 2018, 35(11):1324-1328. DOI: 10.3969/j.issn.1005-202X.2018.11.016.
[54] 常明向,吴梅梅,李瀚旻.姜黄素联合索拉非尼增强抑制肝癌细胞 HepG-2 的作用及其机制[J].中西医结合肝病杂志, 2016, 26(5):277-280. DOI: 10.3969/j.issn.1005-0264.2016.05.008.
[55] JIN X, WANG J, SHEN H F, et al. Curcumin co-treatment ameliorates resistance to gefitinib in drug-resistant NCI-H1975 lung cancer cells[J]. J Tradit Chin Med, 2017, 37(3): 355-360.
[56] CHEN P, HUANG H P, WANG YI, et al. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death[J]. J Exp Clin Cancer Res, 2019, 38(1):254. DOI: 10.1186/s13046-019-1234-8. (
